Delivery Order SPE2DB20D3303-SPE2DB25FA2MM
- Not listed
- The Defense Logistics Agency awarded a $1,306.78 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Zepbound 5 mg/0.5 mL pens. This competitive award, with a completion date of July 30, 2025, represents a child delivery order under AmerisourceBergen's broader pharmaceutical supply arrangements with the federal government. The order will be fulfilled from the vendor's Conshohocken, Pennsylvania location, where the company operates as a major...
- The Defense Logistics Agency awarded a $6,970.68 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injectors. The contract is a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, and will be fulfilled at the contractor's Conshohocken, Pennsylvania facility. This award represents a non-set-aside competitive procurement, demonstrating AmerisourceBergen's continued capability to meet federal pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $2,675.26 to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pens. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 8, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting open competition among qualified vendors. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pens in 0.5 mL quantities, with a contract ceiling value of $2,287.80 and an ultimate completion date of August 14, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and represents a small-value transaction under AmerisourceBergen's larger pharmaceutical supply contract vehicle. The place of...
- The Defense Logistics Agency awarded a delivery order valued at $10,167.94 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injections on August 11, 2025, with completion targeted for August 12, 2025. This firm fixed-price delivery order, issued without a set-aside designation, represents a competitive award under AmerisourceBergen's broader pharmaceutical supply arrangement with the federal government. The product will be delivered to the company's corporate...
- The Defense Logistics Agency awarded a $28,634.71 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pen injectors on August 11, 2025. This non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999, which runs through December 2026. The performance location is the company's corporate office in Conshohocken, Pennsylvania, with...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $5,360.72 for Zepbound 7.5 mg/0.5 mL pens on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitive, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's role as a...
- The Defense Logistics Agency awarded a $57,854.15 delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Zepbound 5 mg/0.5 mL pens. This non-set-aside, firm fixed-price contract represents a child delivery order executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through December 2026. The delivery order will be fulfilled at the contractor's corporate office location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pen injections (0.5 mL units) with a ceiling value of $1,659.37. This firm fixed-price delivery order, which is set to be completed by August 15, 2025, will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania facility. The award represents a non-competitive delivery order issued under AmerisourceBergen's existing indefinite delivery...
- The Defense Logistics Agency awarded a $28,552.60 delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injectors. This is a firm fixed-price delivery order with an ultimate completion date of August 8, 2025, to be fulfilled at the contractor's location in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation and represents a child order under AmerisourceBergen's larger contract vehicle with...
- SPE2DB20D3303Indefinite Delivery Contract
- SPE2DB20D3303-SPE2DB25FA2MMDelivery Order
The Defense Logistics Agency awarded a $1,525.20 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pens. The contract, which is a child order under a larger vehicle, carries an ultimate completion date of August 14, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This award was competitively awarded with no set-aside designation, reflecting AmerisourceBergen's demonstrated capability to meet federal pharmaceutical procurement requirements. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. Zepbound, a GLP-1 receptor agonist, represents the type of specialty pharmaceutical medication supplied under this contract to support Defense Health Agency and other federal healthcare system requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.5k | 8/13/25 |